Senator Wyden's amendment, which was tabled, required, as a condition of receiving a grant or contract from the National Institutes of Health, assurance from an academic institution or other entity to transfer to the NIH director a percentage of funds made available from licenses or sales of a broad range of pharmaceuticals.